Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Biotechnol J. 2017 Sep 28;13(2):10.1002/biot.201700093. doi: 10.1002/biot.201700093

Figure 2.

Figure 2

Effect of RA-associated nuclear hormone receptor agonists on BMEC barrier fidelity. A) Experimental timeline for application of RA-signaling associated nuclear hormone receptor agonists during iPSC differentiation to BMECs. B) D10 TEER following D6-D8 treatment with RA signaling associated nuclear hormone receptor agonists: 10 μM BMS753 (RARα agonist; n = 7), 10 μM BMS453 (RARβ agonist and RARα/γ antagonist; n = 7), 1 μM CD1530 (potent RARγ agonist; n = 7), 10 μM CD3254 (RXRα agonist; n = 7), 10 μM DA (pan-RXR agonist; n = 3). Error bars represent standard error of the mean. ANOVA followed by Dunnett’s test; * p < 0.05 vs. control.